Trial Profile

Phase II Non Randomized Clinical Trial of NIVOLUMAB/IPILIMUMAB Maintenance Following First-line Chemotherapy in Unresectable Locally Advanced or Metastatic Urothelial Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Transitional cell carcinoma; Urethral cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms VEXILLUM

Most Recent Events

24 Apr 2026 Status changed from active, no longer recruiting to completed.
24 Sep 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Sep 2025.
24 Sep 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com